Breaking News Instant updates and real-time market news.

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09

NuCana reports additional data on NUC-1031 in advanced biliary tract cancer

NuCana announced combined results from cohorts one and two of the ABC-08 study at the European Society for Medical Oncology Congress 2018 in Munich, Germany. In this Phase Ib multi-center, open-label study in front-line treatment of patients with advanced biliary tract cancer, Acelarin combined with cisplatin was observed to continue to achieve approximately a doubling of the response rate expected with the standard of care, gemcitabine plus cisplatin. In addition, results showed the combination was well-tolerated and several patients achieved significant reductions in their tumor volume as well as further tumor shrinkage over time. Fourteen patients with advanced/metastatic biliary tract cancer received Acelarin and cisplatin on days one and eight of a three-week cycle. In the intent-to-treat group of patients, a Complete Radiological Response was achieved in one patient and a Partial Response in six patients, resulting in an Objective Response Rate of 50%. In the eleven Efficacy Evaluable patients, an Objective Response Rate of 64% was achieved. Additionally, the combination of Acelarin and cisplatin was well-tolerated over multiple cycles with no unexpected adverse events, no dose-limiting toxicities, no discontinuations due to Acelarin-associated toxicity and no Grade 4 adverse events. Based on these data from the ABC-08 study and discussions with the U.S. Food and Drug Administration, NuCana anticipates initiating a global randomized Phase III clinical study comparing Acelarin and cisplatin with gemcitabine and cisplatin in patients with front-line advanced biliary tract cancer.

  • 21

    Oct

NCNA NuCana
$18.90

1.9 (11.18%)

10/18/18
PIPR
10/18/18
INITIATION
Target $36
PIPR
Overweight
NuCana initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro started NuCana with an Overweight rating and $36 price target, stating that data for its lead product, Acelarin, have "strongly" pointed towards platform validation. He sees an opportunity for the drug in platinum-resistant ovarian cancer and sees the potential for it to "establish a new frontline standard of care in biliary tract cancer," Catanzaro tells investors.
10/23/17
WBLR
10/23/17
INITIATION
WBLR
Outperform
NuCana initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started NuCana with an Outperform rating saying her probability-adjusted net present value model derives a fair value of $35 per share at the end of 2018 just based on the company's lead two assets. The analyst forecasts global peak sales of Acelarin in the first four indications, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, biliary cancer, and pancreatic cancer-at GBP 800M with 40%-60% probabilities of success. She estimates NUC-3373 to generate peak sales of GBP 960M in the first two indications, advanced colorectal and breast cancers, with a 20% probability of success.
10/23/17
SBSH
10/23/17
INITIATION
Target $23
SBSH
Buy
NuCana initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz started NuCana with a Buy rating and $23 price target. The company's technology platform produces "much-improved versions of decades-old chemo drugs, with minimal innovation risk," the analyst contends.
10/23/17
COWN
10/23/17
INITIATION
COWN
Outperform
NuCana initiated with an Outperform at Cowen

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
03/25/19
03/25
14:17
03/25/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
03/25/19
03/25
14:16
03/25/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLK

BlackRock

$415.08

-1.92 (-0.46%)

, APO

Apollo Global

$27.93

-0.07 (-0.25%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Periodicals
BlackRock, Varde to make rival offers for Banca Carige, Reuters reports »

Varde Partners and…

BLK

BlackRock

$415.08

-1.92 (-0.46%)

APO

Apollo Global

$27.93

-0.07 (-0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

F

Ford

$8.53

0.005 (0.06%)

14:10
03/25/19
03/25
14:10
03/25/19
14:10
Options
Ford puts lead calls 6:1 »

Ford puts lead calls 6:1.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ASND

Ascendis Pharma

$115.50

-3.71 (-3.11%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Ascendis Pharma announces results of study of hypoparathyroidism at ENDO 2019 »

Ascendis Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.31

-2.8 (-1.47%)

14:07
03/25/19
03/25
14:07
03/25/19
14:07
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple says Apple TV+ will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

IP

International Paper

$44.43

0.03 (0.07%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Options
International Paper call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.74

-2.37 (-1.24%)

14:05
03/25/19
03/25
14:05
03/25/19
14:05
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple CEO Tim Cook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

14:05
03/25/19
03/25
14:05
03/25/19
14:05
General news
Treasury Action: the $40 B 2-year note sale Tuesday »

Treasury Action: the $40…

AAPL

Apple

$188.48

-2.63 (-1.38%)

, ROKU

Roku

$67.67

4.15 (6.53%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Roku, Amazon.com »

Apple bringing Apple TV…

AAPL

Apple

$188.48

-2.63 (-1.38%)

ROKU

Roku

$67.67

4.15 (6.53%)

AMZN

Amazon.com

$1,762.35

-2.61 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

  • 29

    Mar

  • 04

    Apr

  • 03

    Jun

AAPL

Apple

$188.51

-2.6 (-1.36%)

, SNE

Sony

$42.00

-0.09 (-0.21%)

14:03
03/25/19
03/25
14:03
03/25/19
14:03
Hot Stocks
Breaking Hot Stocks news story on Apple, Sony »

Apple bringing Apple TV…

AAPL

Apple

$188.51

-2.6 (-1.36%)

SNE

Sony

$42.00

-0.09 (-0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

OESX

Orion Energy

$0.91

0.017 (1.90%)

, TM

Toyota

$120.19

0.39 (0.33%)

13:57
03/25/19
03/25
13:57
03/25/19
13:57
Hot Stocks
Orion CEO sees $11M Letter of Intent as 'very significant win' »

In an exclusive interview…

OESX

Orion Energy

$0.91

0.017 (1.90%)

TM

Toyota

$120.19

0.39 (0.33%)

F

Ford

$8.55

0.03 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

ANF

Abercrombie & Fitch

$25.25

0.73 (2.98%)

13:55
03/25/19
03/25
13:55
03/25/19
13:55
Options
Abercrombie & Fitch put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$188.61

-2.5 (-1.31%)

13:54
03/25/19
03/25
13:54
03/25/19
13:54
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple announces Apple TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.61

-2.5 (-1.31%)

13:53
03/25/19
03/25
13:53
03/25/19
13:53
Hot Stocks
Apple introduces Apple Arcade game subscription service »

Apple announced Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:51
03/25/19
03/25
13:51
03/25/19
13:51
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade pricing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.60

-2.51 (-1.31%)

13:50
03/25/19
03/25
13:50
03/25/19
13:50
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.08

-3.03 (-1.59%)

13:48
03/25/19
03/25
13:48
03/25/19
13:48
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.34

-2.77 (-1.45%)

13:47
03/25/19
03/25
13:47
03/25/19
13:47
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will include…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

AAPL

Apple

$188.34

-2.77 (-1.45%)

13:46
03/25/19
03/25
13:46
03/25/19
13:46
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple Arcade will include…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

RLGY

Realogy

$11.82

0.02 (0.17%)

13:45
03/25/19
03/25
13:45
03/25/19
13:45
Options
Realogy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:45
03/25/19
03/25
13:45
03/25/19
13:45
General news
Euro$ interest rate futures are cracking higher »

Euro$ interest rate…

AAPL

Apple

$188.55

-2.56 (-1.34%)

, GS

Goldman Sachs

$188.87

0.3 (0.16%)

13:43
03/25/19
03/25
13:43
03/25/19
13:43
Hot Stocks
Apple partners with Goldman Sachs, Mastercard to launch Apple Card »

Apple (AAPL) announced…

AAPL

Apple

$188.55

-2.56 (-1.34%)

GS

Goldman Sachs

$188.87

0.3 (0.16%)

MA

MasterCard

$229.47

-1.3 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 15

    Apr

  • 03

    Jun

  • 25

    Jun

AAPL

Apple

$188.55

-2.56 (-1.34%)

13:43
03/25/19
03/25
13:43
03/25/19
13:43
Hot Stocks
Breaking Hot Stocks news story on Apple »

Apple aanounces Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 03

    Jun

CCL

Carnival

$56.60

-0.13 (-0.23%)

, MKC

McCormick

$142.96

0.66 (0.46%)

13:42
03/25/19
03/25
13:42
03/25/19
13:42
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CCL

Carnival

$56.60

-0.13 (-0.23%)

MKC

McCormick

$142.96

0.66 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 26

    Mar

  • 27

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.